DexCom, Inc. $DXCM Shares Purchased by Defilade Capital Management L.P.

Defilade Capital Management L.P. increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 120.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 538,762 shares of the medical device company’s stock after buying an additional 293,881 shares during the period. DexCom accounts for 4.8% of Defilade Capital Management L.P.’s holdings, making the stock its 5th biggest position. Defilade Capital Management L.P. owned about 0.14% of DexCom worth $33,834,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of DexCom in the fourth quarter worth about $483,356,000. AQR Capital Management LLC grew its position in shares of DexCom by 597.8% during the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after acquiring an additional 2,658,158 shares during the period. Employees Provident Fund Board acquired a new stake in shares of DexCom during the 4th quarter valued at about $145,352,000. J. Stern & Co. LLP increased its stake in shares of DexCom by 2,114.8% in the 4th quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock valued at $106,323,000 after purchasing an additional 1,529,641 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of DexCom by 271.4% in the 1st quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock valued at $129,699,000 after purchasing an additional 1,509,219 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft started coverage on DexCom in a research report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price target on the stock. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Truist Financial set a $93.00 target price on DexCom and gave the company a “buy” rating in a research report on Friday. Robert W. Baird set a $105.00 price target on shares of DexCom in a research note on Friday. Finally, JPMorgan Chase & Co. boosted their price target on shares of DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $88.12.

DexCom Price Performance

Shares of DexCom stock opened at $83.45 on Monday. The stock has a market capitalization of $31.49 billion, a P/E ratio of 32.98, a PEG ratio of 1.36 and a beta of 1.41. The business has a 50 day simple moving average of $73.14 and a two-hundred day simple moving average of $69.19. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $87.00. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same period in the previous year, the company posted $0.48 earnings per share. The business’s revenue was up 13.1% on a year-over-year basis. As a group, analysts predict that DexCom, Inc. will post 2.6 EPS for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares in the company, valued at approximately $1,500,670.07. This trade represents a 3.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction on Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the sale, the director directly owned 52,852 shares in the company, valued at approximately $3,917,918.76. This trade represents a 7.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,506 shares of company stock worth $7,205,258 in the last quarter. 0.28% of the stock is owned by insiders.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly beat and higher outlook: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus, while revenue rose 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by strong global demand and broader product access. Reuters article
• Positive Sentiment: Product and market expansion: Growth is being supported by the G7 15 Day continuous glucose monitor, with DexCom targeting nearly 50% U.S. conversion by year-end, as well as expanded access and continued international growth. Margin improvement also contributed to a more constructive 2026 earnings narrative. Seeking Alpha article
• Positive Sentiment: Broad analyst support: Mizuho raised its price target to $95, Royal Bank of Canada and Wells Fargo lifted targets to $90, and UBS reaffirmed a Buy rating with a $96 target. Benchmark also reaffirmed Buy, although its $82 target is below the referenced trading level. Benzinga analyst updates
• Neutral Sentiment: Mixed valuation signals: JPMorgan raised its target substantially to $82 but retained a Neutral rating, indicating that some analysts view much of the improved outlook as already reflected in the stock.
• Negative Sentiment: Insider selling: Quiver Quantitative data shows 14 insider sales and no purchases during the past six months. This is a potential cautionary signal, although it has not outweighed the earnings-driven optimism. Quiver Quantitative analysis

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.